ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Hydration Dos & Don’ts
Hydration talk. When I am sick, I always seek out a bowl of “chicken noodle soup.” In every culture, there’s always something soothing, whether it is a stew, soup, or something more substantial when you are feeling down. It works because these types of food can give you the essential nutrition you need when you…
-
Dr. Mark Awad & Dr. Roberto Chiarle join ALKtALK
Mark Awad, MD, PhD Clinical Director, Thoracic Oncology Treatment Center Assistant Professor of Medicine, Harvard Medical School I hope everyone is safe, warm, and healthy tonight. I am the Clinical Director of Thoracic Oncology at Dana Farber Cancer Institute in Boston, MA. I did Medical School at John’s Hopkins, medical residency at Mass General, and…
-
Ensartinib: the unknown TKI
Ensartinib (x396) is a medicine made by Xcovery, a biotech company based in Florida. It works closely with another company called Betta Pharmaceuticals in China for many of its trials. Currently, there is an eXalt3 (phase 3) clinical trial to compare Ensartinib against Xalkori (not currently recruiting). Originally, there was a phase1/2 trial done in…
-
Dr. Jessica Lin and Dr. Ibiayi Dagogo-Jack join ALKtALK
Dr. Jessica Lin Attending physician, Hematology/Oncology, Massachusetts General Hospital Instructor, Medicine, Harvard Medical School Dr. Lin: I first began interested in oncology in my undergraduate years. I started out as a biochemist, but I met a mentor who was a pediatric oncologist who also worked in basic research. He really inspired me and made me…
-
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
An updated review of the most current targeted therapies in NSCLC (non-small cell lung cancer) by targetable mutation. Dr. David Konig, Dr. Spasenija S. Prince, and Dr. Sacha I Rothschild did a great review on the current status of targeted therapy in NSCLC (non-small cell lung cancer). Because of the advancement of molecular diagnostics and…
-
Dr. Christine Lovly joins ALKtALK
Editor’s Note: A special thanks to Marc Rosenzweig for creating and scheduling the ALKtALK programs. Alice Chou graciously committed her time to transcribe thisALKtALK with Dr. Lovly so that it would be available here for other ALK patients. Thank you so much Alice Chou for your hard work and generosity!! . . and a big…
-
Update on ALK Clinical Trials currently recruiting and a caregiver’s perspective on why treatment at an NCI cancer center prolongs survival
Like all trips to the emergency room, this one was unexpected. But my husband was shocked and overwhelmed to hear he had stage 4 lung cancer. With tumors throughout his chest and in his brain, his prognosis seemed dismal. The oncologist assigned by the hospital did not ease our panic. His bedside manner was characterized…
-
Dr. Ross Camidge joins ALKtALK
Editor’s Note: A special thanks to Marc Rosenzweig for creating and scheduling the ALKtALK programs. Alice Chou graciously committed her time to transcribe the January ALKtALK with Dr. Camidge so that it would be available here on our blog for other ALK patients.. Thank you so much Alice Chou for your hard work and generosity!!…
-
Dr. Alice Shaw joins ALKtALK
Editor’s Note: A special thanks to Marc Rosenzweig for creating and scheduling the ALKtALK programs. Alice Chou graciously committed her time to transcribe the January ALKtALK with Dr. Shaw so that it would be available here for other ALK patients.. Thank you so much Alice Chou for your hard work and generosity!! . . and…
-
Normal ALK Function
What function does ALK serve in a healthy human? Read on for some fascinating proposed hypotheses. We all know that a faulty ALK activation domain leads to all kinds of trouble. But what is the normal function of the ALK protein? ALK was identified in 1997 by two groups, Iwahara et. al. and Morris et…